论文部分内容阅读
目的探讨硼替佐米节律性化疗对老年多发性骨髓瘤(MM)的疗效研究。方法对8例初治伴严重并发症老年MM患者均给予节律性化疗:硼替佐米1 mg/m2·qw+地塞米松10 mg/qw,4周为1个疗程(VD),休息1个月,重复上述方案,共化疗6个疗程。结果 8例患者中有效率为100%。1～2个疗程后完全缓解6例,完全缓解率为75%,另2例患者化疗1～2个疗程后获得部分缓解,但分别于化疗后6个月～1年死于感染和出血。结论硼替佐米节律性化疗对伴有严重并发症的MM患者,疗效显著,且患者耐受性好,不良反应少。节律性化疗在MM中的作用机制与抑制新生血管的生成是否有关,有待进一步研究探讨。
Objective To investigate the curative effect of bortezomib rhythmic chemotherapy on elderly multiple myeloma (MM). Methods Routine chemotherapy was given in 8 MM patients with newly diagnosed MM with severe complications: bortezomib 1 mg / m 2 · qw + dexamethasone 10 mg / qw for 4 weeks for 1 course of treatment (VD) and 1 month of rest , Repeat the above program, a total of 6 courses of chemotherapy. Results The effective rate was 100% in 8 patients. After 1 ~ 2 courses of complete remission in 6 cases, the complete remission rate was 75%. The other 2 patients received partial remission after 1 ~ 2 courses of chemotherapy, but died of infection and bleeding 6 months to 1 year after chemotherapy respectively. Conclusion Bortezomib rhythmic chemotherapy in patients with severe complications of MM, significant effect, and patients with good tolerance, fewer adverse reactions. Rhythmic chemotherapy in the role of MM and angiogenesis inhibition is related to whether further study to be explored.